precisionmedicineonline1d
NICE Recommends Vertex, CRISPR Therapeutics' Casgevy for Sickle Cell Under Managed Access Deal
The gene-editing treatment will be available to certain patients with sickle cell disease in England as Vertex commits to collecting additional data.
Vertex Pharma Stock Surges After FDA Approves Non-Opioid Pain Drug
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
Nasdaq1mon
2 Biotech Stocks to Buy Hand Over Fist in December
Casgevy will cost $2.2 million in the U.S., but we don't know its price tag in other countries. At any rate, the medicine has massive potential even before we consider potential label expansions.
Vertex Pharmaceuticals' SWOT analysis: cystic fibrosis leader faces pipeline challenges
Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...
Yahoo1mon
Gene therapy uptake in sickle cell stays slow, despite patient interest
Lyfgenia’s label warns of the risk of blood cancer ... at St. Jude Children’s Research Hospital who helped test Casgevy. “It's not just the patient preparation and manufacturing of ...